Presentation (CTI)

OBJECTIVES: Japan’s FY2026 drug pricing reform introduces targeted updates to existing reimbursement mechanisms to balance cost containment and innovation. This study assesses key policy changes and their implications for pricing dynamics and market access.
METHODS: A structured review of Ministry of Health, Labour and Welfare (MHLW) and Chuikyo policy documents (Dec 2025-Feb 2026) was conducted, focusing on NHI price revisions, premium eligibility, and post-launch repricing.
RESULTS: The FY2026 reform reflects incremental tightening rather than structural change, reinforcing cost containment as the primary policy objective. Continued correction of the ~4.8% gap between market and NHI prices underpins a 0.87% price cut, contributing significantly to healthcare savings.
Reforms target both front-end incentives and lifecycle price erosion. The patent-period price maintenance premium (PMP) is tightened through stricter eligibility and removal of certain criteria, reducing access to innovation-linked protection. In parallel, market expansion repricing (MER) becomes more punitive, with price cuts increasing to up to 66.7% for high-revenue products, intensifying pressure on blockbuster therapies.
Lifecycle compression is further accelerated through changes to long-listed products, with earlier and more uniform application of generic-driven price reductions, regardless of substitution rates. Additional updates to foreign price referencing and paediatric premiums improve consistency but do not materially alter pricing flexibility.
Key structural elements, including expansion of cost-effectiveness assessment (CEA), remain deferred, indicating continued policy uncertainty.
CONCLUSIONS: Japan’s FY2026 reform signals a clear direction: tightening price control within an established framework. While innovation incentives are preserved in principle, strengthened repricing and stricter premium eligibility increase downward price pressure across the lifecycle. The absence of structural reform—particularly around CEA—positions the current changes as a transitional step, with further value-based mechanisms likely to follow.